Novel insights in ICU-acquired respiratory muscle dysfunction: implications for clinical care by Jonkman, A.H. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/177443
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
REVIEW Open Access
Novel insights in ICU-acquired respiratory
muscle dysfunction: implications for clinical
care
Annemijn H. Jonkman1, Diana Jansen2 and Leo M. A. Heunks1*
Abstract
This article is one of ten reviews selected from the Annual
Update in Intensive Care and Emergency medicine 2017.
Other selected articles can be found online at http://
ccforum.com/series/annualupdate2017. Further
information about the Annual Update in Intensive Care
and Emergency Medicine is available from http://www.
springer.com/series/8901.
Background
The respiratory muscles drive ventilation. Under normal
conditions, the diaphragm is the main muscle for inspir-
ation, whereas expiration is largely passive, driven by
relaxation of the inspiratory muscles and elastic recoil
pressure of the lung. A disturbance in the balance
between capacity and loading of the inspiratory muscles
will result in respiratory failure. This may occur in the
course of numerous disorders that increase loading of
the diaphragm, such as pneumonia, acute respiratory
distress syndrome (ARDS), acute exacerbation of chronic
obstructive pulmonary disease (COPD) and trauma. On
the other hand, capacity of the respiratory muscles may
be impaired due to congenital myopathies or acquired
muscle dysfunction (e. g., in COPD or cancer cachexia).
Mechanical ventilation can partially or completely
unload the respiratory muscles. Despite being life‐saving,
studies published in the last decade have demonstrated
that respiratory muscle function may further deteriorate
in ventilator bound intensive care unit (ICU) patients.
Respiratory muscle weakness in ventilated ICU patients
is associated with prolonged duration of ventilator
weaning [1] and increased risk of ICU and hospital
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readmission [2]. Therefore, it seems of crucial import-
ance to limit the detrimental effects of critical illness,
and in particular mechanical ventilation, on the respira-
tory muscles. The aim of this chapter is to describe
recent insights into the pathophysiology of diaphragm
dysfunction in ICU patients and how these new findings
may affect clinical care for our patients. We will focus
on studies performed in humans.
Effects of critical illness on diaphragm structure
and function
Effects of critical illness on diaphragm structure
Less than a decade ago, Levine et al. were the first to
describe a rapid loss of diaphragm muscle mass in
patients on controlled mechanical ventilation [3]. Biop-
sies were obtained from 14 brain‐dead organ donors on
controlled mechanical ventilation for 18 to 69 h before
organ harvest. The cross‐sectional area (CSA) of
diaphragm fibers was significantly lower (53 and 57% for
fast‐ and slow‐twitch fibers respectively) compared to
fibers obtained from patients referred for elective lung
cancer surgery. Interestingly, the severity of atrophy was
less pronounced in the pectoralis muscle, indicating that
the diaphragm is much more sensitive to the effects of
disuse. In subsequent studies, it was demonstrated that
the decrease in diaphragm fiber CSA was proportional
to the duration of mechanical ventilation (Pearson r2 =
0.28) [4]. Diaphragm inactivity was associated with
oxidative stress, active caspase‐3 expression and upregu-
lation of mRNAs coding for ligands related to the pro-
teolytic ubiquitin‐proteasome pathway (muscle atrophy
F‐box [MAFBx] and muscle ring finger 1 [MuRF‐1]). In
addition, activation of the lysosomal‐autophagy pathway
was demonstrated in the diaphragm of these brain‐dead
patients ventilated for ±60 h [5]. Very recently, Matecki
et al. demonstrated increased oxidation, nitrosylation and
phosphorylation of the diaphragm sarcoplasmic reticulum
ryanodine calcium release channel in ventilated brain‐
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dead patients [6]. These molecular modifications were as-
sociated with enhanced calcium leak from the channel
(increased open probability). Additional experiments in
mice indicated that leaky ryanodine channels are associ-
ated with diaphragm weakness.
Collectively, these data demonstrate that inactivity of
the diaphragm under controlled mechanical ventilation
is associated with rapid posttranslational protein modifi-
cations, activation of proteolytic pathways and muscle
fiber atrophy. However, these early studies used biopsies
of the diaphragm of brain‐dead patients. This might be
an excellent model for diaphragm disuse associated with
mechanical ventilation, but differences in treatment and
underlying pathophysiology in more representative ICU
patients should be recognized. Hooijman et al. were the
first to study structural, biochemical and functional
modifications of biopsies obtained from the diaphragm
of ventilated ICU patients (n = 22, mean duration on the
ventilator: 7 days, range 14 to 607 h) [7]. These authors
found that both fast‐ and slow‐twitch diaphragm fibers
had a CSA that was approximately 25% smaller than that
of fibers from the diaphragm of patients referred for
elective surgery. Biochemical analysis revealed activation
of the proteolytic ubiquitin‐proteasome pathway. Histo-
logical analysis demonstrated that the number of inflam-
matory cells, including neutrophils and macrophages,
was significantly increased in the diaphragm of ICU
patients; this supports a role for inflammatory mediators
in the development of atrophy or injury. Interestingly,
van Hees et al. demonstrated that plasma from septic
shock patients, but not from healthy subjects, induced
atrophy in (healthy) cultured skeletal muscle myotubes
[8]. This indicates that plasma from septic shock
patients contains molecules with catabolic properties.
Additional experiments presented in that paper suggest
that interleukin (IL)‐6 plays a role in the development of
muscle atrophy in sepsis.
Effect of critical illness on diaphragm function
Structural modifications of the respiratory muscles as
described above may have functional implications. Single
muscle fibers isolated from the diaphragm provide an
excellent model to study contractile protein function.
The force generated by single fibers from the diaphragm
of ICU patients was significantly reduced compared to
fibers from non‐ICU patients [7]. Reduction in force
resulted from loss of contractile proteins (atrophy) and
contractile protein dysfunction.
The gold standard to evaluate in vivo diaphragm
contractile function in ventilated patients is to assess the
change in endotracheal tube pressure induced by mag-
netic stimulation of the phrenic nerves during airway
occlusion (Ptr,magn). The major advantage of this tech-
nique is that it can be performed at the bedside and does
not require patient cooperation. Demoule et al. mea-
sured Ptr,magn within 24 h of mechanical ventilation in
a population of 85 critically ill patients [9]. Of this
group, 54 (64%) patients were diagnosed with diaphragm
dysfunction defined as a Ptr,magn < 11 cmH2O. More
recently, the same investigators confirmed these earlier
findings in 43 ventilated patients [10]; 23 (53%) of these
patients exhibited diaphragm dysfunction at ICU admis-
sion. These are important findings, as they indicate that
other factors besides disuse play a role in the patho-
physiology of respiratory muscle weakness in ICU
patients. In fact, in their earlier study [9], the authors
reported that diaphragm dysfunction was independently
associated with sepsis. Consistent with that study,
Supinski et al. [11] found that measures for in vivo
contractile force were affected more in ventilated pa-
tients with infection than in ventilated patients without
infection.
In a follow up study, Jaber et al. measured Ptr,magn
every 24 to 36 h in ICU patients (n = 6) ventilated for >
5 days [4]. Ptr,magn rapidly declined by approximately
30% in the first 5 to 6 days of controlled mechanical
ventilation. The recent study by Demoule et al. [10] also
assessed Ptr,magn during the ICU stay. In that study,
61% of patients fulfilling criteria for diaphragm dysfunc-
tion at admission had persistent respiratory muscle
weakness while in the ICU. Of the patients with normal
diaphragm function at ICU admission, 55% developed
weakness while on the ventilator. This study demon-
strates that 80% of all patients fulfilling their inclusion cri-
teria (i. e., > 5 days on mechanical ventilation), develop
respiratory muscle weakness at some time while on the
ventilator.
Goligher et al. described the evolution of diaphrag-
matic thickness during mechanical ventilation and its
impact on diaphragm function, assessed with ultrasound
[12]. Changes in diaphragm thickness were found in 56%
of the study population (n = 128). Both loss and gain of
diaphragm thickness were observed during the first week
of ventilation, in 44 and 12% of the patients, respect-
ively. Contractile activity of the diaphragm was esti-
mated as the diaphragm thickening fraction during
maximal inspiratory effort. There was a significant
correlation between the mean diaphragm thickening
fraction during the first 3 days of ventilation and
changes in diaphragm thickness (p = 0.01): a loss of
diaphragm muscle mass was associated with lower con-
tractile activity, while higher contractile activity was
found for patients exhibiting increases in diaphragm
thickness. Both increased and decreased diaphragm
thickness seemed to be modulated by the intensity of
respiratory muscle work performed by the patient,
because the change in diaphragm thickness was inversely
correlated with the driving pressure applied by the
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ventilator over the first 72 h of ventilation (p = 0.04, after
removal of one outlier).
In conclusion, in the last decade our knowledge of the
effects of critical illness and mechanical ventilation on
respiratory muscle function has markedly improved. We
have gained more insight into the pathophysiology,
including molecular pathways, associated with dysfunc-
tion. In addition, it appears that the most important
clinical risk factors for development of dysfunction
include disuse and inflammation/sepsis.
Clinical implications of current knowledge
Monitoring diaphragm function in the ICU
As described above, disuse is proposed to be an import-
ant risk factor for the development of atrophy and
dysfunction of the diaphragm in ventilated patients.
Therefore, a reasonable clinical goal is to limit the dur-
ation of respiratory muscle inactivity by using partially
assisted modes, such as pressure support ventilation as
soon as feasible and safe (fulfilling criteria for lung‐pro-
tective ventilation). It should be recognized that even in
partially assisted modes, full unloading of the diaphragm
may occur ([13]; Fig. 1). Moreover, this study demon-
strated that clinicians are often unable to recognize dia-
phragm inactivity based on pressure and flow signals on
the ventilator screen. Therefore, there may be a role for
more advanced respiratory muscle monitoring tech-
niques [14, 15]. Recently, we reviewed clinically available
methods to monitor respiratory muscle function in
ventilated ICU patients [14].
Today, the state of the art technique for monitoring
diaphragm activity is assessment of the transdiaphrag-
matic pressure (Pdi). This can be estimated by simultan-
eous measurement of esophageal pressure (Pes) and
gastric pressure (Pga) as surrogates for the pleural and
abdominal pressures, respectively. Recently, recommen-
dations for the use of Pes monitoring in ICU patients
were published [16, 17]. Although no reference values
for Pdi are available for critically ill patients, monitoring
will prevent unwanted periods of diaphragm inactivity
due to over‐assist in partially supported modes. In
addition, Pes monitoring enables the clinician to detect
patient‐ventilator asynchronies.
Binding of acetylcholine to the skeletal muscle acetyl-
choline receptor will result in depolarization of the
plasma membrane, which in turn opens calcium release
channels that activate contractile proteins, resulting in
the generation of force. Depolarization of the plasma
membranes can be visualized by electromyography
(EMG). Recently, continuous monitoring of diaphragm
electrical activity (EAdi) has become available for ICU
patients. Neurally‐adjusted ventilator assist (NAVA) is a
relatively new mode for partially assisted ventilation that
uses EAdi to control the ventilator. EAdi is acquired
using a dedicated nasogastric feeding tube with nine
electrodes positioned at the level of the diaphragm
Fig. 1 Ventilator screen of a patient in pressure support mode. Despite the fact that this patient was in a partial assist mode, the diaphragm was
inactive as demonstrated by the absence of diaphragm electrical activity (lower tracing). Technical issues for absence of diaphragm electrical
activity were excluded
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muscle. The electrical activity is shown real‐time on the
ventilator screen (Servo‐i/U, Maquet Sweden), even
when the patient is ventilated in another mode than
NAVA. Therefore, EAdi may be an alternative to esopha-
geal and gastric balloons to monitor diaphragm activity
(Fig. 2). Indeed, absence of EAdi is consistent with
inactivity of the diaphragm, when technical issues have
been excluded. However, conversion of EAdi (in micro-
volt) into pressure has not yet been well validated.
Bellani et al. proposed a proportionality coefficient (pres-
sure‐electrical activity index, PEi) that allows calculation
of pressure generated by the diaphragm from EAdi [18].
Another index derived from the EAdi is the patient‐ven-
tilator breath contribution (PVBC) index, which provides
an estimation of the fraction of breathing effort that is
generated by the patient compared to the total work of
breathing (ventilator + patient). Liu et al. demonstrated
in 12 patients ventilated using the NAVA mode that
PVBC predicts the contribution of the inspiratory mus-
cles versus the pressure delivered by the ventilator [19].
Although both PEi and PVBC may be helpful to limit
the risk of ventilator over‐assist, additional studies are
required before clinical implementation is justified.
Strategies to prevent diaphragm dysfunction
Although respiratory muscle weakness may already be
present at ICU admission [9], many patients develop
weakness while in the ICU [10]. Sepsis is a recognized
risk factor for development of respiratory muscle weak-
ness [10], but apart from appropriate treatment of sepsis,
no specific interventions can be applied to protect the
respiratory muscles. Certain drugs have been associated
with the development of respiratory muscle weakness, in
particular corticosteroids and neuromuscular blockers.
The effect of both drugs, together or separately, on
muscle dysfunction is complex and beyond the scope of
this paper. We refer to an excellent recent review on this
subject [20]. However, it should be noticed that short
periods (48 h) of full neuromuscular blockade are not
associated with the development of clinically relevant
respiratory muscle weakness, because ARDS patients
treated with a neuromuscular blocker were liberated
faster from mechanical ventilation than patients in a pla-
cebo group [21].
As discussed earlier, inactivity appears to be an
important risk factor for the development of respiratory
muscle dysfunction. No clinical studies have compared
the effects of controlled and partially supported modes
on the development of respiratory muscle dysfunction in
humans. Sassoon et al. [22] investigated the effect of
controlled mechanical ventilation or partially supported
modes of mechanical ventilation on diaphragm force‐
velocity relationships in vitro in rabbits. The loss of dia-
phragmatic force‐generating capacity was significantly
less in rabbits on partially supported modes compared
to those receiving controlled mechanical ventilation.
Despite the absence of evidence in humans, from a
physiological perspective it is reasonable to apply par-
tially assisted ventilator modes when feasible and safe.
Recently, it was demonstrated that assisted ventilation in
patients with mild‐to‐moderate ARDS improved patient‐
ventilator interaction and preserved respiratory variabil-
ity, while maintaining lung‐protective ventilation in
terms of tidal volume and lung‐distending pressure [23].
Fig. 2 Physiological tracings of a patient ventilated in partially assisted mode. The electrical activity of the diaphragm (EAdi, lower tracing) reflects
inspiratory effort, as shown by a decrease in esophageal pressure (Pes)
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Nevertheless, in some critically ill patients admitted to
the ICU partially assisted modes are not feasible, for
instance due to very high respiratory drive. In these
patients, high levels of sedation may be required, result-
ing in full unloading of the respiratory muscles. An
interesting hypothesis is that in these patients electrical
activation of the muscles (‘pacing’) may limit develop-
ment of dysfunction. Pavlovic and Wendt were the first
to hypothesize that electrical pacing of the diaphragm
may prevent disuse atrophy and contractile dysfunction
in mechanically ventilated patients [24]. This hypothesis
was based on evidence that electrical pacing of limb
skeletal muscle is an effective therapy to maintain
muscle activity without patient cooperation. For
example, multiple studies have shown that non‐invasive
pacing of the quadriceps in COPD patients improves
muscle performance and exercise capacity [25–27].
Based on the effectiveness of these studies, there is a
growing interest for pacing the respiratory muscles in
the critically ill ventilated patient.
Today, the major clinical application of non‐invasive
pacing of the phrenic nerve has been as a diagnostic
tool, using brief transcutaneous stimuli at the neck for
the evaluation of phrenic nerve conduction time, dia-
phragm contractility and fatigue [28, 29]. However, this
method is not feasible for therapeutic purposes, because
prolonged transcutaneous pacing is uncomfortable for
patients and correct positioning of the stimulator (coil)
is cumbersome in an ICU setting because of its select-
iveness: minor changes in the location of the stimulus
can result in submaximal activation of the phrenic nerve
and co‐activation of other anatomically related nerves.
Although there is no clinical evidence for therapeutic
pacing to reduce diaphragm atrophy and dysfunction
during mechanical ventilation, a few studies have been
conducted. A very novel technique, using transvenous
phrenic nerve pacing, has been investigated recently
[30]. To activate the phrenic nerves bilaterally, a pacing
catheter is introduced in the left subclavian vein and
advanced into the superior vena cava. The preclinical
study in mechanically ventilated pigs showed that loss of
diaphragm muscle mass was attenuated in pigs subjected
to phrenic nerve pacing. Future studies should evaluate
the feasibility of this device in humans.
Strategies to restore respiratory muscle dysfunction
ICU‐acquired respiratory muscle weakness may prolong
duration of mechanical ventilation. Therefore, in diffi-
cult‐to‐wean patients, strategies that improve respiratory
muscle strength are of potential clinical importance. Sur-
prisingly, very few studies have evaluated strategies to
enhance respiratory muscle function in these patients.
We will discuss the role of inspiratory muscle training
and pharmacological interventions.
Inspiratory muscle training
We have recently discussed the rationale for inspiratory
muscle training in ICU patients [31]. Briefly, few studies
have evaluated the effects of inspiratory muscle training
in ICU patients. In the largest trial [32], 69 patients
admitted to a long‐term weaning facility were random-
ized to inspiratory muscle strength training or sham
training. In both groups, endurance training was accom-
plished by progressive spontaneous breathing trials.
Inspiratory muscle strength training significantly
improved inspiratory muscle strength and facilitated
weaning from the ventilator. Importantly, no adverse
effects of inspiratory strength training were reported.
Inspiratory muscle weakness after extubation is associ-
ated with increased risk of ICU and hospital readmission
within 6 weeks after ICU discharge [2]. Therefore, the
recently published trial by Bissett and colleagues [33], in
which 70 ICU patients ventilated for > 7 days were ran-
domized to inspiratory muscle strength training or usual
care after successful extubation (>48 h), is of particular
relevance. Training was performed five days/week for
two weeks. The primary endpoint, respiratory muscle
strength, was significantly improved in the training
group (training: 17% versus control: 6%, p = 0.02), but
this did not result in clinical benefits, such as length of
stay or risk of readmission.
In conclusion, based on these preliminary studies,
inspiratory muscle strength training appears to be effect-
ive in enhancing inspiratory muscle strength and is safe
in ICU patients. Future studies are required to deter-
mine the optimal moment to start inspiratory muscle
training (early versus late in ICU admission) and to
investigate the optimal training protocol.
Pharmacotherapy
In contrast to cardiac muscle dysfunction, surprisingly
no drug is approved to improve respiratory muscle func-
tion. We briefly discuss the role of anabolic hormones
and of the cardiac inotrope, levosimendan. For more
extensive discussion we refer to an earlier review by our
group [31].
Anabolic steroids increase bodyweight, fat‐free mass
and muscle strength in healthy people [34]. Although
many clinical trials have assessed the effects of anabolic
steroids in patients with chronic diseases, they do not
have sufficient statistical power for clinically relevant
endpoints. Pan et al. [35] conducted a meta‐analysis and
selected eight randomized controlled trials investigating
the effects of anabolic steroids in patients with COPD.
They concluded that anabolic steroids improve fat‐free
mass and quality of life, but do not influence inspiratory
muscle strength, although some high quality studies did
demonstrate that anabolic hormones improved inspira-
tory muscle strength when administered during a
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rehabilitation program [36]. No randomized studies have
been performed in weak difficult‐to‐wean ICU patients.
Notably, Takala et al. reported that early administration
of growth hormone increased mortality in ICU patients
[37]. In conclusion, anabolic hormones should not be
routinely used in ICU patients to enhance muscle
strength. Whether they may have a role for difficult‐to‐
wean patients with severe respiratory muscle weakness
remains to be investigated.
Levosimendan is a relatively novel cardiac inotrope,
which enhances the binding of calcium to troponin and
improves contractile efficiency of the muscle fibers. It is
approved for the treatment of heart failure, but exerts
effects in other organs as well [38]. Levosimendan has
been shown to enhance contractile efficiency of muscle
fibers isolated from the diaphragm of healthy subjects
and patients with COPD [39]. Doorduin et al. demon-
strated in healthy subjects that levosimendan reversed
fatigue and improved neuromechanical efficiency of the
diaphragm in vivo [40]. Future studies should evaluate
the effects of levosimendan on respiratory muscle func-
tion in difficult to wean patients.
Conclusion
In the last decade, our understanding of the pathophysi-
ology of ICU‐acquired respiratory muscle weakness has
improved considerably. Molecular mechanisms include
activation of different proteolytic pathways and posttrans-
lational protein modifications, in particular of calcium re-
lease channels. This results in atrophy of respiratory
muscle fibers and dysfunction of the remaining contractile
proteins. Weakness is associated with prolonged mechan-
ical ventilation and increased risk of ICU and hospital re-
admission. Risk factors for the development of respiratory
muscle weakness include sepsis and disuse. In particular,
duration of disuse can be limited in selected patients by
applying appropriate monitoring techniques that help re-
duce over‐assist by the ventilator. Future studies should
reveal the optimal monitoring techniques and the precise
goals of monitoring. In patients who have developed ICU‐
acquired respiratory muscle weakness, no intervention has
been shown to improve outcome. Nevertheless, several
studies have demonstrated that inspiratory muscle
strength training improves strength. No drug has been ap-
proved to improve respiratory muscle function. As
respiratory muscle weakness has detrimental effects on
patient outcomes, clinically effective treatment strategies
are urgently needed.
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